Crinetics (CRNX)’ paltusotine was granted FDA orphan designation status as a treatment of carcinoid syndrome, according to a post to the agency’s website.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position
- Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
- Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating
- Buy Rating Affirmed for Crinetics Pharmaceuticals: Promising Phase 3 Trial of Atumelnant for CAH
- Crinetics Pharmaceuticals Reports Q1 2025 Financial Results